Friedman Joseph H
Brown University Medical School and the Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA.
J Clin Psychiatry. 2004;65 Suppl 9:3-8.
Before atypical antipsychotics were developed, neuroleptics given to patients for the treatment of psychosis often caused movement disorders. Although the role of neuroleptics in the development of tardive dyskinesia was never certain, this adverse effect was of great concern to physicians because its effects could be irreversible and devastating to the patient. It is important to understand whether involuntary movement disorders are an intrinsic part of schizophrenia, because if so, then a certain percentage of patients will develop the dyskinetic syndromes whether they are treated or not. To uncover the role of antipsychotic medications in tardive dyskinesia, it is necessary to examine the descriptions of abnormal movements made by those who were first researching schizophrenia, as well as modern descriptions of neuroleptic-naïve individuals with schizophrenia. The physicians who initially described the syndrome of tardive dyskinesia had observed pre-neuroleptic schizophrenia first hand and saw a difference in the movements of treated and untreated patients. Nevertheless, the idea of a chronic movement disorder caused by treatment with neuroleptics would become controversial for many years. With the development of the atypical antipsychotics, the incidence and prevalence of tardive dyskinesia have dropped remarkably, suggesting that psychosis, its treatment, and dyskinesias are not inextricably linked.
在非典型抗精神病药物研发出来之前,用于治疗精神病的神经阻滞剂常常会导致患者出现运动障碍。尽管神经阻滞剂在迟发性运动障碍发生过程中所起的作用一直不明确,但这种不良反应却引起了医生们的高度关注,因为其影响可能是不可逆的,且会给患者带来极大伤害。了解不自主运动障碍是否是精神分裂症的固有特征非常重要,因为如果是这样的话,那么无论是否接受治疗,一定比例的患者都会出现运动障碍综合征。为了弄清楚抗精神病药物在迟发性运动障碍中的作用,有必要研究最早研究精神分裂症的人对异常运动的描述,以及对未使用过神经阻滞剂的精神分裂症患者的现代描述。最初描述迟发性运动障碍综合征的医生曾亲眼观察过未使用神经阻滞剂的精神分裂症患者,并发现接受治疗和未接受治疗的患者在运动方面存在差异。然而,由神经阻滞剂治疗引起慢性运动障碍的观点在很多年里一直存在争议。随着非典型抗精神病药物的研发,迟发性运动障碍的发病率和患病率显著下降,这表明精神病、其治疗方法和运动障碍并非紧密相连。